Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 3
2013 2
2014 1
2015 5
2016 2
2018 3
2019 4
2020 4
2021 6
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Wolchok JD, et al. J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24. J Clin Oncol. 2022. PMID: 34818112 Free PMC article. Clinical Trial.
PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes. ...Coprimary end points were progression- …
PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab an …
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. Redman MW, et al. Lancet Oncol. 2020 Dec;21(12):1589-1601. doi: 10.1016/S1470-2045(20)30475-7. Epub 2020 Oct 27. Lancet Oncol. 2020. PMID: 33125909 Free PMC article. Clinical Trial.
The biomarker-driven substudies evaluated taselisib (targeting PIK3CA alterations), palbociclib (cell cycle gene alterations), AZD4547 (FGFR alteration), rilotumumab plus erlotinib (MET), talazoparib (homologous recombination repair deficiency), and telisotuzumab vedotin ( …
The biomarker-driven substudies evaluated taselisib (targeting PIK3CA alterations), palbociclib (cell cycle gene alterations), AZD4547 (FGFR …
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G. Dafni U, et al. Ann Oncol. 2019 Dec 1;30(12):1902-1913. doi: 10.1093/annonc/mdz398. Ann Oncol. 2019. PMID: 31566658 Free article.
The PubMed electronic database was searched from inception to 17 December 2018 to identify studies administering TIL-ACT and recombinant interleukin-2 (IL-2) following non-myeloablative chemotherapy in previously treated metastatic melanoma patients. ...The ORR for HD-IL-2 …
The PubMed electronic database was searched from inception to 17 December 2018 to identify studies administering TIL-ACT and recombinant …
Aflibercept, ipilimumab, and vemurafenib.
Hussar DA, Au AY. Hussar DA, et al. J Am Pharm Assoc (2003). 2012 Mar-Apr;52(2):291-4. doi: 10.1331/JAPhA.2012.12512. J Am Pharm Assoc (2003). 2012. PMID: 22370387 Review. No abstract available.
Mycobacterium bovis BCG in metastatic melanoma therapy.
Benitez MLR, Bender CB, Oliveira TL, Schachtschneider KM, Collares T, Seixas FK. Benitez MLR, et al. Appl Microbiol Biotechnol. 2019 Oct;103(19):7903-7916. doi: 10.1007/s00253-019-10057-0. Epub 2019 Aug 12. Appl Microbiol Biotechnol. 2019. PMID: 31402426 Review.
Since then, immunotherapies have been approved for metastatic melanoma (MM) including ipilimumab and pembrolizumab checkpoint inhibitors that help decrease the risk of progression. ...BCG can be administered in combination with chemotherapeutic and immunotherapeutic agents …
Since then, immunotherapies have been approved for metastatic melanoma (MM) including ipilimumab and pembrolizumab checkpoint inhibit …
Cancer Vaccines: A Brief Overview.
Thomas S, Prendergast GC. Thomas S, et al. Methods Mol Biol. 2016;1403:755-61. doi: 10.1007/978-1-4939-3387-7_43. Methods Mol Biol. 2016. PMID: 27076165 Review.
Vaccine types considered include autologous patient-derived immune cell vaccines, tumor antigen-expressing recombinant virus vaccines, peptide vaccines, DNA vaccines, and heterologous whole-cell vaccines derived from established human tumor cell lines. ...In particular, ta …
Vaccine types considered include autologous patient-derived immune cell vaccines, tumor antigen-expressing recombinant virus vaccines …
Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants.
Terrero G, Datta J, Dennison J, Sussman DA, Lohse I, Merchant NB, Hosein PJ. Terrero G, et al. JAMA Oncol. 2022 Jun 1;8(6):1-3. doi: 10.1001/jamaoncol.2022.0611. JAMA Oncol. 2022. PMID: 35446342 Free PMC article.
This case series describes ipilimumab/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency (HRD) pathogenic germline variants (PGVs)....
This case series describes ipilimumab/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous r …
[New immunotherapeutic approaches in oncology and hematology].
Kroemer M, Turco C, Galaine J, Deschamps M, Limat S, Borg C. Kroemer M, et al. Transfus Clin Biol. 2015 Aug;22(3):132-40. doi: 10.1016/j.tracli.2015.05.002. Epub 2015 Jun 9. Transfus Clin Biol. 2015. PMID: 26068883 Review. French.
Dramatic results were obtained with melanoma. Checkpoint inhibitors (pembrolizumab and ipilimumab) have many advantages in terms of rate of objective response and overall survival. ...
Dramatic results were obtained with melanoma. Checkpoint inhibitors (pembrolizumab and ipilimumab) have many advantages in terms of r …
Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies.
Beck A, Reichert JM. Beck A, et al. MAbs. 2011 Sep-Oct;3(5):415-6. doi: 10.4161/mabs.3.5.17334. Epub 2011 Sep 1. MAbs. 2011. PMID: 21785279 Free PMC article.
In the 2010s to date, an additional 3 antibodies (denosumab, belimumab, ipilimumab) have been approved and one antibody-drug conjugate (brentuximab vedotin) is undergoing regulatory review and may be approved in the US by August 30, 2011. ...
In the 2010s to date, an additional 3 antibodies (denosumab, belimumab, ipilimumab) have been approved and one antibody-drug conjugat …
33 results